AbbVie to Boost Oncology Portfolio with $10.1 Billion ImmunoGen Acquisition
- December 01, 2023
AbbVie Inc. is planning to acquire oncology-focused ImmunoGen Inc. in a deal valued at roughly $10.1 billion, the companies announced November 30.
ARTICLE TAGS
You must be logged in to access this content.